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nvolvement, interval between appearance of lesions and diagnosis
nd number of cutaneous lesions in each affected person.
Results: Results showed that cutaneous leishmaniasis was
bserved more in children younger than 15 years-old.
Although, 44.9% of all patients were females and 51.1% were
ales but sex factor of the patients was not statistically signiﬁcant.
his investigation demonstrated that 44.4% had only one lesion.
ore than one skin lesion reported in 55.6% of the patients that is
ndicated that sand- ﬂy, for complete feeding, bites it’s host more
han one time or more than one sand ﬂy bite patients.
Conclusion: In order to prevention of leishmaniasis, health edu-
ation about this disease and also providing protection facilities are
ecommended in endemic areas.
ttp://dx.doi.org/10.1016/j.ijid.2012.05.689
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odeling and simulation to evaluate pyronaridine exposure in
ediatric malaria patients
. Fleckenstein1,∗, J. Methaneethorn1, S. Duparc2, I. Borghini-
uhrer2, C.-S. Shin3, D. Jung4
University of Iowa, Iowa City, IA, USA
Medicines for Malaria Venture, Geneva, Switzerland
Shin Poong Pharmaceuticals, Seoul, Korea, Republic of
Pharmaceutical Research Services, Cupertino, CA, USA
Background: Malaria causes substantial illness and death in
he world’s population, especially in children less than 5 years
ld. Pyronaridine/Artesunate (PA) 3:1 ﬁxed dose combination is
novel artemisinin combination therapy (ACT) in development
or the treatment of acute uncomplicated Plasmodium falciparum
nd blood stage of P. vivax malaria. Tablet (180:60mg PA) and
ediatric granule (60:20mg PA) formulations are under parallel
evelopment for clinical use. The purpose of this study is to use
harmacokinetic modeling and simulation to explore exposure
mong pediatric dosing groups for 3 PA dosing regimens.
Methods: Population pharmacokinetics of pyronaridine was
onducted using non-linear mixed effect modeling. The pharma-
okinetic model incorporated data from healthy (166) and malaria
nfected (642) subjectsparticipating inninePhase I-III clinical trials.
ge ranged from 0.6 to 60 years and weight from 9 to 90.1 kg. Inﬂu-
nces of age, weight, bodymass index,malaria infection, creatinine
learance, alanine aminotransferase, aspartate aminotransferase,
ender, and ritonavir administration on pyronaridine pharmacoki-
etics were evaluated. Monte Carlo simulations were performed to
eﬂect pyronaridine exposure in pediatric malaria patients based
ncurrentdosing recommendations. Typical pyronaridineAUCval-
es expected for pediatric malaria patients of weights between
-20kg were obtained using covariate parameter relationship of
he ﬁnal model and the current dosage recommendations.
Results: Pyronaridine pharmacokinetics was best described by
two-compartment model with ﬁrst order absorption and elim-
nation from the central compartment. Signiﬁcant covariates on
yronaridinepharmacokinetics includedweight on apparent clear-
nce (CL/F), apparent central volume of distribution (V2/F), and
pparent peripheral volume of distribution (V3/F) and malaria
nfection on CL/F, and V2/F. Pyronaridine exposures for pediatricfectious Diseases 16S (2012) e158–e316 e159
malaria patients are shown for 3 PAweight-based dosing regimens.
Figure. Box-plot depicting number of sachets and Ln(AUC)
distribution of pyronaridine based on current dosing recom-
mendations for pediatric malaria patients; bars represent 25th
and 75th percentiles; whiskers represent 10th and 90th per-
centiles.
Conclusion: These results suggest that the use of PK model-
ing and simulation with adult and pediatric data can be used to
select appropriate dosing regimens in children. Simulations were
conducted using population pharmacokinetic modeling to show
weight-based dosing produces consistent pyronaridine exposure
among dosing groups in pediatric malaria patients between 5 and
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Clinical presentations of ALA (amoebic liver abscess) among
tuak consumers in Medan
F. Ginting
Faculty of Medicine University of Sumatera Utara/Adam Malik Central
Hospital, Medan, Indonesia
Background: Amoebiasis is endemic in many tropical countries
including Indoensia. Amoebic liver abscess (ALA) is one of the most
important extraintestinal amoebiasis, which alcoholism is one of
the risk factors. Tuak is a traditional beverage contains 15 – 25%
alcohol inMedan. The presentation of amoebic liver abscess among
tuak consumers in Medan has not been studied.
Objective: To describe the presentation of ALA among tuak con-
sumers in Medan.
Methods: This is an observational study conducted from May
2007 to March 2012 and included all of the patients with amoe-
bic liver abscess. The diagnosis of liver abscess was based on the
clinical appearances and USG. The presentations of ALA which
were recorded include fever, leucocytosis, and hepatomegaly. The
abscess puncture was performed for etiology conﬁrmation. All of
the patients received metronidazole and paramomycin. We per-
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ormed the informed consent for the abscess puncture procedure.
he length of tuak consumption was also recorded.
Results: There were 104 patients conducted the study, 93
89.4%) were men which aged 40 – 49 years old are the highest
revalence (n=28; 26.9%). Tender hepatomegaly was found in 93
89.4%)which 87 (83.6%) among themwere right lobe liver abscess,
ight upper abdominal quadrant pain occurred in 98 (94.2%), fever
n 89 (85.6%), and leukocytosis in 79 (75.9%) patients. A right lobe
epatic abscess was seen in 87 (83.6%) patients. Tuak was con-
umed by 91 (87.5%) for 5-10 years. Liver puncture was performed
n 79 (76%) patients and we evacuated liquid with variable color,
nd thebacterial cultureswere all negative and the amoebawasnot
ound in all of the samples. All of the patients showed improvement
fter medication.
Conclusion: The presentations of ALA in Medan are mainly
ight upper abdominal quadrant pain, fever, tender hepatomegaly,
eukocytosis, affect the righthepatic lobe, age40-49years old,male,
hus a male presented those symptoms with history of tuak con-
umption increases our suspicion of amoebic liver abscess. Amoeba
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ole of vitamin molecules on host gene down regulation and
ffect on Leishmania donovani infection in an experimental ani-
al model
.R. Gogulamudi ∗, R. Sehgal
PGIMER, Chandigarh, India
Background:Vitamins have as long as been recognized for their
rotective role against tuberculosis. Several studieshave shown the
ole of vitamin D status in tuberculosis patients. Recently, a gene
oding for tryptophan-aspartate containing coat protein (TACO)
asbeen recognized toplay a crucial role in the survival ofMycobac-
erium tuberculosis within human macrophages and host molecule
ACOhas been shown toplay a important role in the arrest of such a
aturation process. Studies showed that synergistic action of Vita-
in D3 and Retinoic acid had inherent ability to down-regulate
ACO gene transcription in human macrophages and this leads to
arly maturation of phagosome and pathogen elimination. We are
ostulating that a similar stable association of TACO with phago-
omes would prevent the vacuole from maturation, with a role of
ACO in this process in case of Leishmania.
Methods: The present study evaluated the effect of treatment
ith Vitamin D3/Retinoic acid & Chenodeoxycholic acid/Retinoic
cid combinations on Leishmania donovani infection in BALB/c
ouse model. Animals were sacriﬁced at different time intervals.
arasite load was determined in the impression smears of liver and
pleen of control and drug treated animals. histological examina-
ions at different time intervels.
Results: Itwas found theparasite loadandweights of spleenand
iver increased till day 28 post infection in control mice, whereas in
ice treated with above-mentioned drugs there was a signiﬁcant
ecline inweights of the organs andparasite load ondays 21 and28fectious Diseases 16S (2012) e158–e316
post treatment. There was also a marked healing of post treatment
and also observed in histology.
Conclusion: Our results elucidate that the Vitamin D3/Retinoic
acid and Chenodeoxycholic acid/Retinoic Acid treatment led to sig-
niﬁcant suppression of weights of spleen, liver and parasite load.
Healing responses in histological specimens of above molecules
treated animals response suggested that the drug treatment down
regulated TACO gene expression as was observed in our in-vitro
experiments. Vit-D3/Retinoic acid combination showing a signiﬁ-
cant level of parasite suppression with better immune modulation
in comparison with the Chenodeoxycholic acid/retinoic acid com-
bination. These observations suggest that Vit-D3/Retinoic acid and
Chenodeoxycholic acid/Retinoic acidmay possibly be an important
adjunct to the treatment of Leishmaniasis.
http://dx.doi.org/10.1016/j.ijid.2012.05.692
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Differentially expressed Leishmaniamajorgenesmight discrim-
inate between clinical isolates of contrasted virulence
F. Guerfali 1,∗, R.M. Sghaier1, D. Laouini1, L. Guizani-Tabbane2, F.
Ottones3, K. Ben-Aissa2, J. Marti 3, K. Dellagi1
1 Institut Pasteur de Tunis, Tunis-Belvedere, Tunisia
2 Institut Pasteur de Tunis, Tunis, Tunisia
3 Université Montpellier II, Montpellier, France
Background: Leishmaniasis is a vector borne parasitic disease
affectingmillions of peopleworldwide that causes different clinical
manifestations classiﬁedas cutaneous,muco-cutaneous, or visceral
depending on the infecting specie. Zoonotic cutaneous leishma-
niasis (ZCL) caused by Leishmania (L.) major clinically presents as
localized self-healing cutaneous soreswith a broad range of clinical
variations. Whether this clinical spectrum could reﬂect a differen-
tial role playedby L.major in disease outcomeand severity has been
very little investigated.
Our hypothesis is that genetic variation among L. major par-
asites, possibly acting at the level of virulence genes expression,
might impact, in concert with the host immune response, on the
clinical polymorphism of ZCL (severe vs. benign disease or asymp-
tomatic infection).
In an attempt to correlate parasite diversity with disease
outcome, our goal was to establish a list of selected putative
virulence-associated genes that could discriminate between L.
major isolates collected from the ﬁeld.
Methods: Human blood derived macrophages were in vitro
infected with two L. major strains expressing contrasted viru-
lence (high vs. low virulence) according to their experimental
pathogenicity in Balb/C. Our approach was ﬁrst based on a high
throughput transcriptome analysis, namely Serial Analysis of Gene
Expression. More than two hundred parasite transcripts showed
differential expression between the high- or low-virulent strains
at their intracellular infectious stage. Among transcripts that we
could conﬁdently assign to their related gene, four (LmjF26.1710,
LmjF28.2205, LmjF33.1740 and LmjF33.1750) were tested on
human macrophages from donors infected with different parasite
strains.
